Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy
Key Points
Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.
Meanwhile, the quarter-end position value rose by $273.57 million, reflecting both additional shares and stock price movement.
The position now accounts for 3.26% of reportable AUM, placing it outside the fund’s top five holdings.
- 10 stocks we like better than Kodiak Sciences ›
On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 2,608,696 shares of Kodiak Sciences (NASDAQ:KOD), an estimated $53.42 million trade based on quarterly average pricing.
What happened
According to its SEC filing dated February 17, 2026, Baker Bros. Advisors LP increased its position in Kodiak Sciences (NASDAQ:KOD) by 2,608,696 shares during the fourth quarter of 2025. The estimated transaction value was $53.42 million, calculated using the average unadjusted closing price for the quarter. The value of the Kodiak Sciences holding at quarter-end rose by $273.57 million, a figure that includes both the additional shares and stock price movement.
What else to know
- Kodiak Sciences represents 3.26% of 13F reportable AUM after the trade.
- Top holdings after the filing:
- INCY: $3.04 billion (17.8% of AUM)
- ONC: $2.67 billion (15.7% of AUM)
- MDGL: $1.25 billion (7.3% of AUM)
- INSM: $1.15 billion (6.7% of AUM)
- ACAD: $1.15 billion (6.7% of AUM)
- As of February 23, 2026, KOD shares were priced at $25.91, up a staggering 480% over the past year and significantly outperforming the S&P 500’s roughly 13% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Market Capitalization | $1.6 billion |
| Net Income (TTM) | ($217.34 million) |
| Price (as of market close February 23, 2026) | $25.91 |
Company snapshot
- Kodiak Sciences develops and advances therapeutics for retinal diseases, with a lead product candidate, KSI-301, in Phase IIb/III trials targeting wet age-related macular degeneration and other retinal disorders.
- The firm operates a clinical-stage biopharmaceutical business model, generating value through the research, development, and potential commercialization of proprietary drug candidates.
- It focuses on developing therapeutics to treat retinal diseases as a clinical stage biopharmaceutical company based in the US.
Kodiak Sciences is a clinical-stage biotechnology company specializing in innovative therapies for retinal diseases.
What this transaction means for investors
Kodiak’s momentum is building into 2026. Tarcocimab and KSI-501 are both enrolled in the Phase 3 DAYBREAK study in wet AMD, with topline data expected in the third quarter, while GLOW2 in diabetic retinopathy is on track for this quarter. KSI-101 is advancing in PEAK and PINNACLE for MESI, targeting a new segment within retinal disease. The opportunity sits inside a roughly $15 billion anti-VEGF marketplace.
The financials reflect that ambition. Third quarter R&D spending reached $50.5 million, with a quarterly net loss of $61.5 million. Cash stood at $72 million at September 30 before a $184 million December raise.
Within a portfolio already heavy in oncology and metabolic biotech, a 3% weight is meaningful but not dominant. For long-term investors, the thesis hinges on non-inferiority and durability. If Phase 3 data validate the ABC platform, Kodiak could compete head-on in retinal vascular disease. If not, a 480% run leaves little margin for error.
Should you buy stock in Kodiak Sciences right now?
Before you buy stock in Kodiak Sciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kodiak Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BeOne Medicines Ag and Incyte. The Motley Fool has a disclosure policy.
Recommended Articles
